Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

need for women and for physicians seeking alternatives to hormone therapies."

Dr. Alan Altman, Assistant Clinical Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School and an expert on menopause, commented "Physicians are now seeing an epidemic of vaginal symptoms, such as dryness, irritation and sexual pain, in post-menopausal patients as a result of large numbers of women stopping hormone treatment due to fear instilled by what they have read about the Women's Health Initiative Study. Chronic symptoms such as these have a major adverse impact on quality of life for these women and highlight the need for new treatment options in those wanting to avoid estrogen use."

About Postmenopausal Vaginal Syndrome

Postmenopausal Vaginal Syndrome (PVS) is a chronic condition characterized by vaginal symptoms including dryness, sexual pain (dyspareunia), and irritation. Declining estrogen levels during menopause may cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as atrophy. Dryness and irritation associated with decreases in vaginal secretions often cause pain or bleeding during sexual intercourse. The decline in estrogen also contributes to an increase in vaginal pH, creating an environment more susceptible to infection. There are more than 64 million women in the United States who are over 40 years old. It is estimated that up to 40% of post-menopausal women will have symptoms of PVS. Current treatments approved for this condition all contain estrogen, administered either orally or locally in the vagina. Other currently available SERMs do not have an effect on vaginal tissue and may induce hot flashes.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active cl
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... advance from Hercules Technology Growth Capital, Inc. (NYSE: ... and final advance under the Loan and Security Agreement ... , Alimera Sciences Limited, entered into with Hercules ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Jan. 31, 2012 Halozyme Therapeutics, Inc. (NASDAQ: ... Phase 1 proof-of-concept and local tolerability study of HTI-501 ... 8th World Congress of the International Academy of Cosmetic ... commencement of the Phase 2 portion of the clinical ...
... LAKES, N.J., Jan. 31, 2012 The Board of Directors of ... declared a quarterly dividend of 45 cents per common share, payable ... 2012. The indicated annual dividend rate is $1.80 per share. ... is a leading global medical technology company that develops, manufactures and ...
Cached Medicine Technology:HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 2HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 3
(Date:9/30/2014)... [Brown University] Autism is no stranger to the ... African nation is access to clinical services, including reliable ... measure, for example, validated for use in Swahili, a ... study, however, researchers at Brown University and the University ... that they implemented at two sites in the country ...
(Date:9/30/2014)... passed in 2003 to slow the spiraling costs of ... Medicare patients has had no meaningful impact on cancer ... the Journal of Clinical Oncology published online ... to treat colorectal and lung cancers, and did not ... drugs following the implementation of the recent Medicare law ...
(Date:9/30/2014)... 2014 Dynamic health trends, changing ... in the Bread Production industry over the past ... moderate their consumption of a variety of industry ... shrunk the market for white loaf bread and ... by introducing more nutritious products to attract health-conscious ...
(Date:9/30/2014)... (FQHCs) granted new patient appointments to Medicaid beneficiaries ... primary care practices (non-FQHCs), in addition to charging ... new 10-state University of Pennsylvania study published this ... data from a previous "secret shopper" study conducted ... FQHCs community health clinics that receive federal ...
(Date:9/30/2014)... September 30, 2014(BRONX, NY)Medications are the leading cause of ... analysis of death certificates from 1999 to 2010, conducted ... and Albert Einstein College of Medicine of Yeshiva ... Journal of Allergy and Clinical Immunology , also ... was particularly high among older people and African-Americans and ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2
... Field, IRVING, Texas, Sept. 11 Over 90 ... solicitations during their training,and 80 percent received two dozen ... Merritt, Hawkins & Associates, a national physician,search firm based ... "Like blue chip athletes, new doctors are the ...
... 11 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX,: HAE), ... plasma-derived protein products for commercialization,disclosed today the ... on the use of its proprietary lead ... preventing the formation of post-surgical,adhesions in a ...
... scoop, NEW YORK, Sept. 11 If ... impact a person,s body and skin, it,s a ... procedures last,year to improve their appearances. However, New ... can improve your appearance,without going under the knife!, ...
... will be of great interest to employers and employee benefit brokers ... grounbreaking wellness and health management tool designed to help control costs ... ... (PRWEB) September 11, 2008 -- U.S. Preventive Medicine, the leader in ...
... for the medical tourism industry. Working closely with medical tourism ... trip cancellation insurance products to meet the needs of the industry. ... ... Clements International develops unique suite of insurance solutions for the medical ...
... a traumatic injury can have serious and long-lasting ... the largest-ever U.S. study evaluating the impact of ... and Research Center, the University of Washington, and ... found that post-traumatic stress disorder and depression were ...
Cached Medicine News:Health News:Survey: New Doctors Receive Dozens of Job Solicitations 2Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 2Health News:Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model 3Health News:Insider Secrets for Beautiful Skin 2Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 2Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 3Health News:U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan 4Health News:Clements International Develops Insurance for Medical Tourism Industry 2Health News:National study finds post-traumatic stress disorder common among injured patients 2